# A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

> **NCT01395524** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 302 (actual)

## Conditions studied

- Opioid-Induced Constipation (OIC)

## Interventions

- **DRUG:** NKTR-118
- **DRUG:** NKTR-118
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01395524
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395524, "A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01395524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*